05:43 AM EDT, 04/28/2025 (MT Newswires) -- Medtronic ( MDT ) said Saturday that a clinical study for the Hugo robotic-assisted surgery system met both primary safety and effectiveness endpoints.

The rates of grade 3 or higher complications were favorably below performance goals, and the study's 98.5% surgical success rate was well above the performance goal of 85%, the company said. The study included 137 patients who underwent urologic procedures using Hugo.

Medtronic ( MDT ) also said it submitted the Hugo system to the US Food and Drug Administration for a urologic indication in Q1.

The company's shares were up 1% in recent premarket activity Monday.